

Company registration number: 446358

Clonminch Pharmacy Limited

Unaudited abridged financial statements

for the financial year ended 31 August 2025

Clonminch Pharmacy Limited

Contents

	Page
Directors responsibilities statement	1
Balance sheet	2 - 3
Notes to the abridged financial statements	4 - 9

Clonminch Pharmacy Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Clonminch Pharmacy Limited

Balance sheet As at 31 August 2025

	Note	2025		2024	
		€	€	€	€
Fixed assets					
Tangible assets	9	334,763		334,229	
Financial assets	10	764,613		610,818	
			1,099,376		945,047
Current assets					
Stocks	11	140,877		133,817	
Debtors	12	180,825		170,616	
Cash at bank and in hand		482,123		475,102	
		803,825		779,535	
Creditors: amounts falling due within one year	13	(180,869)		(158,459)	
Net current assets			622,956		621,076
Total assets less current liabilities			1,722,332		1,566,123
Net assets			1,722,332		1,566,123
Capital and reserves					
Called up share capital presented as equity			100		100
Profit and loss account			1,722,232		1,566,023
Shareholders funds			1,722,332		1,566,123

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Clonminch Pharmacy Limited

Balance sheet (continued)

As at 31 August 2025

We, as directors of Clonminch Pharmacy Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 17 December 2025 and signed on behalf of the board by:

Diarmuid Herlihy
Director

Evelyn Herlihy
Director

Clonminch Pharmacy Limited

Notes to the abridged financial statements Financial year ended 31 August 2025

1. General information

The financial statements comprising the Profit and Loss Account, the statement of income and retained earnings, the Balance Sheet and the related notes constitute the individual financial statements of Clonminch Pharmacy Limited for the financial year ended 31st August 2025.

The company is a private company limited by shares (registered under Part 2 of Companies Act 2014), incorporated and registered in the Republic of Ireland (CRO number 446358). The address of the registered office is Clonminch, Tullamore, Co. Offaly, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report.

Currency

The financial statements have been presented in the Euro currency (€) which is also the functional currency of the company.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (FRS 102), applying section 1A of that standard.

3. Summary of Significant Accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 The financial reporting standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council. The company qualifies as a small company for the period, as defined by section 280A of the Act, in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and Section 1A of FRS 102.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Clonminch Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment	- 12.5%
Motor vehicles	- 12.5%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Financial assets

Financial assets are initially recorded at cost, and subsequently stated at cost less any provision for diminution in value. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Stocks

Stocks are measured at the lower of cost and net realisable value using the first in first out method. In the case of finished goods and work in progress, cost is defined as the aggregate cost of raw material, direct labour and the attributable proportion of direct production overheads based on a normal level of capacity. Net realisable value is based on normal selling price, less further costs expected to be incurred to completion and disposal.

Turnover

Turnover is stated net of trade discounts, volume rebates, VAT and similar taxes and derives from the provision of goods and services falling within the company's ordinary activities. Turnover on the sale of goods is recognised when the company has transferred the significant risks and rewards of ownership in the goods, which usually takes place when the goods are physically delivered to the buyer.

Government grants

Grants are recognised at fair value of the asset receivable using the accruals model when there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Grants towards capital expenditure are credited to deferred income and are released to the profit and loss account over the expected useful life of the related assets, by equal annual instalments. Grants towards revenue expenditure are released to the profit and loss account as the related expenditure is incurred.

Retirement benefit costs

The company operates a defined contribution scheme. Retirement benefit contributions in respect of the scheme for employees are charged to the profit and loss account as they become payable in accordance with the rules of the scheme. The assets are held separately from those of the company in an independently administered fund. Differences between the amounts charged in the profit and loss account and payments made to the retirement benefit scheme are treated as assets or liabilities.

Short term employee benefits

Short term benefits, including holiday pay, are recognised as an expense in the period in which employees have become entitled to the benefits as a result of service rendered to the company.

Clonminch Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Taxation

The charge for taxation is based on the profit for the financial year and is calculated with reference to the tax rates applying at the financial year end date in the jurisdiction where the tax rate is applied. Deferred taxation is not recognised.

Financial Instruments

Ordinary Share Capital

The ordinary share capital of the company is presented as equity.

Cash and Cash equivalents

Cash consists of cash on hand and demand deposits.

Other financial assets

Other financial assets, including trade debtors for goods sold to customers on short-term credit, are measured at the transaction price including transaction costs.

Other financial liabilities

Other financial liabilities, including trade creditors arising from goods purchased from suppliers on short term credit, are measured at transaction price less transaction costs.

Judgements

Going concern

The directors consider it appropriate to prepare the financial statements on a going concern basis.

Impairment of Stocks

The company holds stock amounting to €140,877 (2023: €133,817) at the financial year end date. The directors are of the view that an adequate allowance has been made to reflect the possibilities of stock being sold at less than cost.

4. Operating profit

Operating profit is stated after charging/(crediting):

	2025	2024
	€	€
Depreciation of tangible assets	27,714	26,297
(Gain)/loss on disposal of tangible assets	9,287	-
Foreign exchange differences	-	25
	<u> </u>	<u> </u>

5. Profit before tax

Profit is stated after charging/(crediting):

	2025	2024
	€	€
Depreciation of tangible assets	27,714	26,297
	<u> </u>	<u> </u>

Clonminch Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

6. Directors remuneration

The directors aggregate remuneration was as follows:

	2025	2024
	€	€
Emoluments in respect of qualifying services	222,000	217,000
Pension contributions to defined contribution plans in respect of qualifying services	84,400	96,548
	<u>306,400</u>	<u>313,548</u>

The number of directors to whom retirement benefits are accruing under the pension scheme in respect of qualifying services is 2 (2024: 2).

7. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 13 (2024: 11).

The aggregate payroll costs incurred during the financial year were:

	2025	2024
	€	€
Wages and salaries	585,089	526,685
Social insurance costs	39,911	34,348
Other retirement benefit costs	106,620	111,542
	<u>731,620</u>	<u>672,575</u>

8. Retirement benefit commitments

	2025	2024
	€	€
Retirement benefit charge	<u>106,620</u>	<u>111,542</u>

Defined contribution scheme

The company operates a defined contribution scheme for its employees. The scheme is externally financed in that the assets of the scheme are held separately from those of the company in an independently administered fund.

Clonminch Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025

9. Tangible assets

	Freehold property	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
Cost				
At 1 September 2024	257,325	401,722	45,250	704,297
Additions	-	6,930	49,600	56,530
Disposals	-	-	(45,250)	(45,250)
At 31 August 2025	<u>257,325</u>	<u>408,652</u>	<u>49,600</u>	<u>715,577</u>
Depreciation				
At 1 September 2024	-	353,100	16,968	370,068
Charge for the financial year	-	21,514	6,200	27,714
Disposals	-	-	(16,968)	(16,968)
At 31 August 2025	<u>-</u>	<u>374,614</u>	<u>6,200</u>	<u>380,814</u>
Carrying amount				
At 31 August 2025	<u>257,325</u>	<u>34,038</u>	<u>43,400</u>	<u>334,763</u>
At 31 August 2024	<u>257,325</u>	<u>48,622</u>	<u>28,282</u>	<u>334,229</u>

10. Financial assets

	Other investments other than loans	Total
	€	€
Cost		
At 1 September 2024	610,818	610,818
Additions	204,407	204,407
Disposals	(50,250)	(50,250)
Other movements	(362)	(362)
At 31 August 2025	<u>764,613</u>	<u>764,613</u>
Carrying amount		
At 31 August 2025	<u>764,613</u>	<u>764,613</u>
At 31 August 2024	<u>610,818</u>	<u>610,818</u>

Clonminch Pharmacy Limited

**Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025**

11. Stocks		2025	2024
		€	€
Finished goods and goods for resale		140,877	133,817
		<u> </u>	<u> </u>
12. Debtors		2025	2024
		€	€
Trade debtors		120,291	112,581
Other debtors		57,176	58,035
Prepayments		3,358	-
		<u> </u>	<u> </u>
		180,825	170,616
		<u> </u>	<u> </u>
All debtors are due within one year.			
13. Creditors: amounts falling due within one year		2025	2024
		€	€
Trade creditors		147,128	126,357
Other creditors including tax and social insurance		29,421	27,782
Accruals		4,320	4,320
		<u> </u>	<u> </u>
		180,869	158,459
		<u> </u>	<u> </u>
14. Appropriations of profit and loss account		2025	2024
		€	€
At the start of the financial year		1,566,023	1,434,325
Profit for the financial year		156,209	131,698
		<u> </u>	<u> </u>
At the end of the financial year		1,722,232	1,566,023
		<u> </u>	<u> </u>
15. Approval of financial statements			

The board of directors approved these abridged financial statements for issue on 17 December 2025.